文献速递传染病防控与疫情报告免疫规划

在本氏烟草中生成的具有强效狂犬病中和活性的单链抗体片段的体外与体内评价

In vitro and in vivo evaluation of a single chain antibody fragment generated in planta with potent rabies neutralisation activity.
PubMed 文献 · Vaccine · 2018-03-06

研究评估基于强效体外中和狂犬病病毒的单克隆抗体构建的单链抗体片段(ScFv),在本氏烟草(Nicotiana benthamiana)中瞬时表达,并化学偶联针对中枢神经系统烟碱型乙酰胆碱受体(nAchR)结合的29氨基酸肽段(ScFv/RVG)。该偶联分子在体外能结合nAchR并比ScFv更高效地进入神经元细胞;体内采用错开给药(感染前4小时、感染后2天或感染后4天)评估中和能力,并与HRIG及法匹拉韦(Favipiravir,T-705)直接比较。研究提示ScFv/RVG偶联策略可能有助于设计针对脑内狂犬病病毒感染的新型工具。

要点

  • ScFv/RVG偶联分子在体外能结合nAchR并比ScFv更高效进入神经元细胞。
  • 体内采用感染前4小时、感染后2天或感染后4天的错开给药方案评估ScFv/RVG中和病毒能力。
  • ScFv/RVG与HRIG及法匹拉韦直接比较,以判断治疗小鼠脑内ScFv生物利用度是否更高。

核心结论

  • 研究提示ScFv/RVG偶联策略可能有助于设计针对脑内狂犬病病毒感染的新型工具。

研究设计与样本

  • 基于强效体外中和狂犬病病毒的单克隆抗体构建单链抗体片段(ScFv),在本氏烟草中瞬时表达,并化学偶联针对中枢神经系统烟碱型乙酰胆碱受体(nAchR)结合的29氨基酸肽段(ScFv/RVG)。
  • 体内采用错开给药方案,分别在感染前4小时、感染后2天或感染后4天接种ScFv/RVG,以评估其体内中和病毒能力。
  • 将ScFv/RVG与HRIG及法匹拉韦(Favipiravir,T-705)直接比较,以判断治疗小鼠脑内ScFv生物利用度是否更高。

主要发现

  • ScFv/RVG在体外能结合nAchR,并比ScFv更高效地进入神经元细胞。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rabies causes more than 60,000 human deaths annually in areas where the virus is endemic. Importantly, rabies is one of the few pathogens for which there is no treatment following the onset of clinical disease with the outcome of infection being death in almost 100% of cases. Whilst vaccination, and the combination of vaccine and rabies immunoglobulin treatment for post-exposure administration are available, no tools have been identified that can reduce or prevent rabies virus replication once clinical disease has initiated. The search for effective antiviral molecules to treat those that have already developed clinical disease associated with rabies virus infection is considered one of the most important goals in rabies research. The current study assesses a single chain antibody molecule (ScFv) based on a monoclonal antibody that potently neutralises rabies in vitro as a potential therapeutic candidate. The recombinant ScFv was generated in Nicotiana benthamiana by transient expression, and was chemically conjugated (ScFv/RVG) to a 29 amino acid peptide, specific for nicotinic acetylcholine receptor (nAchR) binding in the CNS. This conjugated molecule was able to bind nAchR in vitro and enter neuronal cells more efficiently than ScFv. The ability of the ScFv/RVG to neutralise virus in vivo was assessed using a staggered administration where the molecule was inoculated either four hours before, two days after or four days after infection. The ScFv/RVG conjugate was evaluated in direct comparison with HRIG and a potential antiviral molecule, Favipiravir (also known as T-705) to indicate whether there was greater bioavailability of the ScFv in the brains of treated mice. The study indicated that the approach taken with the ScFv/RVG conjugate may have utility in the design and implementation of novel tools targetting rabies virus infection in the brain.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Phoolcharoen W, Banyard AC, Prehaud C, et al. In vitro and in vivo evaluation of a single chain antibody fragment generated in planta with potent rabies neutralisation activity. Vaccine. 2018. PMID: 29523449. doi:10.1016/j.vaccine.2018.02.057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。